Company · Mississauga, Ontario, Canada
Hoffmann-La Roche Limited
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 195
- 72 authorized now
- Natural health products
- 0
- 0 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 555
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| ACTEMRAStatus since May 2010 | 02350092 | Marketed | |
| ACTEMRAStatus since May 2010 | 02350106 | Marketed | |
| ACTEMRAStatus since May 2010 | 02350114 | Marketed | |
| ACTEMRAStatus since May 2014 | 02424770 | Marketed | |
| ACTEMRAStatus since Jan 2019 | 02483327 | Marketed | |
| ACTIVASE RT-PAStatus since Dec 1996 | 02147440 | Marketed | |
| ACTIVASE RT-PAStatus since Apr 1998 | 02225689 | Marketed | |
| ALECENSAROStatus since Oct 2016 | 02458136 | Marketed | |
| AVASTINStatus since Nov 2005 | 02270994 | Marketed | |
| CATHFLOStatus since Sep 2002 | 02245859 | Marketed | |
| CELLCEPTStatus since Dec 1995 | 02192748 | Marketed | |
| CELLCEPTStatus since Nov 1998 | 02237484 | Marketed | |
| CELLCEPTStatus since Aug 2002 | 02242145 | Marketed | |
| CELLCEPT I.V.Status since Dec 1999 | 02240347 | Marketed | |
| COLUMVIStatus since Jul 2023 | 02536552 | Marketed | |
| COLUMVIStatus since Jul 2023 | 02536560 | Marketed | |
| COTELLICStatus since Apr 2016 | 02452340 | Marketed | |
| ENSPRYNGStatus since Aug 2020 | 02499681 | Marketed | |
| ERIVEDGEStatus since Aug 2013 | 02409267 | Marketed | |
| ESBRIETStatus since Jul 2017 | 02464489 | Marketed | |
| ESBRIETStatus since Jul 2017 | 02464500 | Marketed | |
| EVRYSDIStatus since May 2021 | 02514931 | Marketed | |
| EVRYSDIStatus since Nov 2025 | 02560747 | Marketed | |
| GAZYVAStatus since Nov 2014 | 02434806 | Marketed | |
| HEMLIBRAStatus since Oct 2018 | 02479621 | Marketed | |
| HEMLIBRAStatus since Oct 2018 | 02479648 | Marketed | |
| HEMLIBRAStatus since Feb 2019 | 02479656 | Marketed | |
| HEMLIBRAStatus since Nov 2018 | 02479664 | Marketed | |
| HEMLIBRAStatus since Dec 2025 | 02556049 | Marketed | |
| HEMLIBRAStatus since Jan 2026 | 02556057 | Marketed | |
| HERCEPTINStatus since Aug 1999 | 02240692 | Marketed | |
| HERCEPTIN SCStatus since Oct 2018 | 02480697 | Marketed | |
| ITOVEBIStatus since Apr 2025 | 02555476 | Marketed | |
| ITOVEBIStatus since Apr 2025 | 02555484 | Marketed | |
| KADCYLAStatus since Oct 2013 | 02412365 | Marketed | |
| KADCYLAStatus since Oct 2018 | 02473224 | Marketed | |
| LUNSUMIOStatus since May 2026 | 02565226 | Marketed | |
| LUNSUMIO SCStatus since Jun 2026 | 02567369 | Marketed | |
| LUNSUMIO SCStatus since Jun 2026 | 02567377 | Marketed | |
| OCREVUSStatus since Sep 2017 | 02467224 | Marketed | |
| PERJETAStatus since May 2013 | 02405016 | Marketed | |
| PERJETA-HERCEPTINStatus since May 2013 | 02405024 | Marketed | |
| PHESGOStatus since Apr 2021 | 02512912 | Marketed | |
| PHESGOStatus since Apr 2021 | 02512920 | Marketed | |
| PIASKYStatus since Nov 2025 | 02558262 | Marketed | |
| POLIVYStatus since Nov 2020 | 02499614 | Marketed | |
| POLIVYStatus since Oct 2021 | 02515431 | Marketed | |
| PROLOPA CAP 100-25Status since Dec 1977 | 00386464 | Marketed | |
| PROLOPA CAP 200-50Status since Dec 1977 | 00386472 | Marketed | |
| PROLOPA CAP 50-12.5Status since Dec 1981 | 00522597 | Marketed | |
| PULMOZYMEStatus since Jun 1998 | 02046733 | Marketed | |
| RITUXANStatus since Mar 2000 | 02241927 | Marketed | |
| RITUXAN SCStatus since Nov 2016 | 02457350 | Marketed | |
| RITUXAN SCStatus since Apr 2018 | 02473976 | Marketed | |
| ROZLYTREKStatus since Mar 2020 | 02495007 | Marketed | |
| ROZLYTREKStatus since Mar 2020 | 02495015 | Marketed | |
| TAMIFLUStatus since Dec 1999 | 02241472 | Marketed | |
| TAMIFLUStatus since Dec 2008 | 02304848 | Marketed | |
| TAMIFLUStatus since Dec 2008 | 02304856 | Marketed | |
| TAMIFLUStatus since Sep 2012 | 02381842 | Marketed | |
| TECENTRIQStatus since May 2017 | 02462990 | Marketed | |
| TECENTRIQStatus since Oct 2019 | 02492393 | Marketed | |
| TECENTRIQ SCStatus since May 2024 | 02546310 | Marketed | |
| TNKASEStatus since Oct 2001 | 02244826 | Marketed | |
| TNKASEStatus since Aug 2026 | 02562804 | Marketed | |
| VABYSMOStatus since Jul 2022 | 02527618 | Marketed | |
| VABYSMOStatus since Jun 2025 | 02554003 | Marketed | |
| XOFLUZAStatus since Sep 2025 | 02496364 | Marketed | |
| XOFLUZAStatus since Jan 2026 | 02496372 | Marketed | |
| XOFLUZAStatus since Mar 2025 | 02524163 | Marketed | |
| ZELBORAFStatus since Mar 2012 | 02380242 | Marketed | |
| SUSVIMOStatus since Sep 2022 | 02530589 | Approved | |
| ACTIVASE RT-PA INJStatus since Jul 1998 | 00771473 | Cancelled Post Market | |
| ANAPOLON 50 TABLETS 50MGStatus since Mar 1999 | 02162679 | Cancelled Post Market | |
| ANEXATE INJ 0.1MG/MLStatus since May 2012 | 00874019 | Cancelled Post Market | |
| AUREO S 700G PREMIXStatus since Jul 2000 | 02230809 | Cancelled Post Market | |
| AUREO S-700 BEEF CATTLE VITAMIN PREMIX CRUMBLESStatus since Jul 2000 | 00613983 | Cancelled Post Market | |
| AUREO SP 250G PREMIXStatus since Jul 2000 | 02230721 | Cancelled Post Market | |
| AUREOMIX 625G PREMIXStatus since Jul 2000 | 02230722 | Cancelled Post Market | |
| AUREOMYCIN 100G PREMIXStatus since Jul 2000 | 02230724 | Cancelled Post Market | |
| AUREOMYCIN 50G PREMIXStatus since Jul 2000 | 02230723 | Cancelled Post Market | |
| AUREOMYCIN VITAMIN PREMIX CRUMBLESStatus since Jul 2000 | 00613975 | Cancelled Post Market | |
| AVATEC PREMIX 150GM/KGStatus since Jul 2000 | 00598925 | Cancelled Post Market | |
| BACIFERM 50 PREMIXStatus since Jul 2000 | 02230720 | Cancelled Post Market | |
| BACTRIM DS ROCHE TABStatus since Jul 2001 | 00371823 | Cancelled Post Market | |
| BACTRIM ROCHE INJStatus since Mar 2000 | 00550078 | Cancelled Post Market | |
| BACTRIM ROCHE SUSPENSION PAEDIATRICStatus since Jul 2001 | 00272485 | Cancelled Post Market | |
| BACTRIM ROCHE TABStatus since Jul 2000 | 00272469 | Cancelled Post Market | |
| BEZALIP TAB 200MGStatus since Jul 2001 | 02084082 | Cancelled Post Market | |
| BONDRONATStatus since May 2006 | 02232770 | Cancelled Post Market | |
| BOVATEC MEDICATED PREMIX 150GM/KGStatus since Jul 2000 | 01923897 | Cancelled Post Market | |
| CARDENE 20MG CAPSULESStatus since Jul 2001 | 02162741 | Cancelled Post Market | |
| CARDENE 30MG CAPSULESStatus since Jul 2001 | 02162733 | Cancelled Post Market | |
| CASIRIVIMAB AND IMDEVIMABStatus since Jun 2024 | 02516705 | Authorization By Interim Order Revoked | |
| CASIRIVIMAB AND IMDEVIMABStatus since Jun 2024 | 02516691 | Authorization By Interim Order Revoked | |
| COREG 12.5MGStatus since Jul 2001 | 02240810 | Cancelled Post Market | |
| COREG 25MGStatus since Jul 2001 | 02240811 | Cancelled Post Market | |
| COREG 3.125MGStatus since Jul 2001 | 02240808 | Cancelled Post Market | |
| COREG 6.25MGStatus since Jul 2001 | 02240809 | Cancelled Post Market | |
| CYGRO 1% PREMIXStatus since Jul 2000 | 02230778 | Cancelled Post Market | |
| CYTOVENE - CAP 250MGStatus since Aug 2007 | 02186802 | Cancelled Post Market | |
| CYTOVENE, 500 MGStatus since Aug 2007 | 02240362 | Cancelled Post Market | |
| DEMADEX INJECTION - 10MG/MLStatus since Jul 2000 | 02129094 | Cancelled Post Market | |
| DEMADEX TABLETS - 100MGStatus since Jul 2000 | 02129035 | Cancelled Post Market | |
| DEMADEX TABLETS - 10MGStatus since Jul 2000 | 02129019 | Cancelled Post Market | |
| DEMADEX TABLETS - 20MGStatus since Jul 2000 | 02129027 | Cancelled Post Market | |
| DEMADEX TABLETS - 5MGStatus since Jul 2000 | 02129000 | Cancelled Post Market | |
| DILATREND - TAB 25MGStatus since Jul 2017 | 02155680 | Cancelled Pre Market | |
| DILATREND - TAB 50MGStatus since Jul 2017 | 02155699 | Cancelled Pre Market | |
| ESBRIETStatus since Jul 2023 | 02393751 | Cancelled Post Market | |
| FANSIDAR TABLETSStatus since Jul 2000 | 00692719 | Cancelled Post Market | |
| FORTOVASE ROCHEStatus since Mar 2007 | 02239083 | Cancelled Post Market | |
| FUZEONStatus since Mar 2025 | 02247725 | Cancelled Post Market | |
| GAVRETOStatus since Feb 2025 | 02517590 | Cancelled Post Market | |
| HIVID TAB 0.375MGStatus since Jul 2003 | 01990918 | Cancelled Post Market | |
| HIVID TAB 0.75 MGStatus since Jul 2006 | 01990896 | Cancelled Post Market | |
| INHIBACE TAB 1MGStatus since Jul 2010 | 01911465 | Cancelled Post Market | |
| INVIRASEStatus since Jan 2021 | 02279320 | Cancelled Post Market | |
| INVIRASE - CAP 200MGStatus since Dec 2018 | 02216965 | Cancelled Post Market | |
| KYTRIL 1MG/1MLStatus since Jan 2012 | 02088371 | Cancelled Post Market | |
| KYTRIL TABLETS 1MGStatus since Nov 2015 | 02185881 | Cancelled Post Market | |
| LARIAM TAB 250MGStatus since May 2013 | 02018055 | Cancelled Post Market | |
| LECTOPAM TAB 1.5MGStatus since Jul 2006 | 00682314 | Cancelled Post Market | |
| LECTOPAM TAB 3MGStatus since Feb 2018 | 00518123 | Cancelled Post Market | |
| LECTOPAM TAB 6MGStatus since Mar 2018 | 00518131 | Cancelled Post Market | |
| MANERIX TAB 100MGStatus since Dec 1997 | 00899348 | Cancelled Post Market | |
| MIRCERAStatus since Jul 2017 | 02307995 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308002 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308010 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308029 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308037 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308045 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308053 | Cancelled Pre Market | |
| MIRCERAStatus since Jun 2023 | 02308061 | Cancelled Pre Market | |
| MIRCERAStatus since Jun 2023 | 02308088 | Cancelled Pre Market | |
| MIRCERAStatus since Jun 2023 | 02308096 | Cancelled Pre Market | |
| MIRCERAStatus since Jun 2023 | 02308118 | Cancelled Pre Market | |
| MIRCERAStatus since Jun 2023 | 02308126 | Cancelled Pre Market | |
| MIRCERAStatus since Jun 2023 | 02308134 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308142 | Cancelled Pre Market | |
| MIRCERAStatus since Jul 2017 | 02308150 | Cancelled Pre Market | |
| MOBIFLEX TAB 20MGStatus since Jul 2001 | 00884367 | Cancelled Post Market | |
| NAPROSYN 250MG TABLETSStatus since Jan 2002 | 02162474 | Cancelled Post Market | |
| NAPROSYN 375MG TABLETSStatus since Jun 2001 | 02162482 | Cancelled Post Market | |
| NAPROSYN 500 MG SUPPOSITORIESStatus since Nov 2002 | 02162458 | Cancelled Post Market | |
| NAPROSYN 500 MG TABLETSStatus since Jul 2002 | 02162490 | Cancelled Post Market | |
| NAPROSYN E 250MG TABLETS - ECTStatus since Feb 2014 | 02162792 | Cancelled Post Market | |
| NUTRISEL 200 PWRStatus since Sep 1999 | 02046628 | Cancelled Post Market | |
| NUTRISEL 2000 PWRStatus since Sep 1999 | 02046601 | Cancelled Post Market | |
| NUTROPIN - KIT PWS(10MG) & LIQ(10ML) IM SCStatus since Dec 2013 | 02216191 | Cancelled Post Market | |
| NUTROPIN - KIT PWS(5MG) & LIQ(10ML) IM SCStatus since Jul 2011 | 02216183 | Cancelled Post Market | |
| NUTROPIN AQ - SC 5MG/MLStatus since Apr 2013 | 02229722 | Cancelled Post Market | |
| NUTROPIN AQ NUSPIN 10Status since Jan 2025 | 02376393 | Cancelled Post Market | |
| NUTROPIN AQ NUSPIN 20Status since Jan 2025 | 02399083 | Cancelled Post Market | |
| NUTROPIN AQ NUSPIN 5Status since Jan 2025 | 02399091 | Cancelled Post Market | |
| NUTROPIN AQ PEN CARTRIDGEStatus since Oct 2017 | 02249002 | Cancelled Post Market | |
| OSTAC CAP 400MGStatus since Oct 2006 | 01927078 | Cancelled Post Market | |
| PEGASYSStatus since Jul 2017 | 02248078 | Cancelled Post Market | |
| PEGASYS RBVStatus since Jul 2018 | 02253410 | Cancelled Post Market | |
| PEGASYS RBVStatus since Jul 2018 | 02253429 | Cancelled Post Market | |
| PROTROPIN - KIT IM SC 10MG/VIALStatus since Feb 2005 | 02204576 | Cancelled Post Market | |
| PROTROPIN - KIT IM SC 5MG/VIALStatus since Jul 2003 | 02204584 | Cancelled Post Market | |
| ROBENZ MEDICATED PREMIXStatus since Jul 2000 | 02230777 | Cancelled Post Market | |
| ROCALTROL ORAL SOLUTION 1MCG/MLStatus since Jun 2013 | 00824291 | Cancelled Post Market | |
| ROCEPHIN INJ 10GM/VIALStatus since Jul 2009 | 00851957 | Cancelled Post Market | |
| ROCEPHIN PWS 1GM/VIALStatus since Oct 2011 | 00657417 | Cancelled Post Market | |
| ROCEPHIN PWS 2GM/VIALStatus since Jul 2009 | 00657409 | Cancelled Post Market | |
| ROCEPHIN PWS INJ 0.25GM/VIALStatus since Jun 2012 | 00657387 | Cancelled Post Market | |
| ROCEPHIN PWS INJ 1GM/VIALStatus since Jul 2003 | 00894699 | Cancelled Post Market | |
| ROFERON A SOLN INJ 6 MILLIONStatus since Aug 1997 | 00812498 | Cancelled Post Market | |
| ROFERON A STERILE PWS 18M UNIT/VIALStatus since Sep 1996 | 01912003 | Cancelled Post Market | |
| ROFERON A STERILE PWS 3M UNIT/VIALStatus since Sep 1996 | 01911988 | Cancelled Post Market | |
| ROFERON A STERILE PWS 9M UNIT/VIALStatus since Sep 1996 | 01911996 | Cancelled Post Market | |
| ROFERON-A SOL INJ 3MILLION IU/VIALStatus since Aug 1997 | 00812501 | Cancelled Post Market | |
| ROFERON-A SOLN-LIQ IM SC 4.5MILLION I.U/MLStatus since Nov 1999 | 02217023 | Cancelled Post Market | |
| ROFERON-A SOLN-LIQ IM SC 9MILLION I.U./MLStatus since Nov 2004 | 02217058 | Cancelled Post Market | |
| ROFERON-A SOLUTION 18 MILLION I.U./3MLStatus since Jul 2005 | 02217066 | Cancelled Post Market | |
| ROFERON-A SOLUTION 3 MILLION I.U./MLStatus since Jul 2005 | 02217015 | Cancelled Post Market | |
| ROFERON-A SOLUTION 6 MILLION I.U./MLStatus since Jul 2000 | 02217031 | Cancelled Post Market | |
| ROFERON-A SOLUTION INJ 36000000UNIT/MLStatus since Jun 1997 | 00891002 | Cancelled Post Market | |
| ROFERON-A SOLUTION INJ. 9MILLION I.U./0.9MLStatus since Aug 1997 | 02019914 | Cancelled Post Market | |
| ROMET-30 PREMIXStatus since Jul 2000 | 00797162 | Cancelled Post Market | |
| TAMIFLU ORAL SUSPENSIONStatus since Dec 2013 | 02245549 | Cancelled Post Market | |
| TARCEVAStatus since Oct 2024 | 02269007 | Cancelled Post Market | |
| TARCEVAStatus since Oct 2024 | 02269015 | Cancelled Post Market | |
| TARCEVAStatus since Oct 2024 | 02269023 | Cancelled Post Market | |
| TASMARStatus since Jan 1999 | 02235914 | Cancelled Post Market | |
| TASMARStatus since Jan 1999 | 02235921 | Cancelled Post Market | |
| TICLID 250MG TABLETSStatus since Jul 2006 | 02162776 | Cancelled Post Market | |
| TORADOL IM 30MG/MLStatus since Jan 2011 | 02162652 | Cancelled Post Market | |
| VALIUM 10 TABStatus since Jul 2001 | 00013293 | Cancelled Post Market | |
| VALIUM INJ ROCHE 5MG/MLStatus since Jul 2000 | 00012874 | Cancelled Post Market | |
| VERSED INJ 1MG/MLStatus since Jul 2004 | 00784516 | Cancelled Post Market | |
| VERSED INJ 5MG/MLStatus since Jun 2004 | 00766011 | Cancelled Post Market | |
| ZENAPAX 5MG/MLStatus since Oct 2011 | 02241473 | Cancelled Post Market |
Notices of Compliance
Newest first.
- COLUMVISeptember 28, 2026 · NOC 38357 · Supplement to a New Drug Submission (SNDS)
- OCREVUSSeptember 17, 2026 · NOC 38303 · Supplement to a New Drug Submission (SNDS)
- LUNSUMIO; LUNSUMIO SCAugust 17, 2026 · NOC 38119 · Supplement to a New Drug Submission (SNDS)
- TAMIFLUAugust 5, 2026 · NOC 38048 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQ; TECENTRIQ SCJuly 31, 2026 · NOC 38034 · Supplement to a New Drug Submission (SNDS)
- ALECENSAROJuly 17, 2026 · NOC 37922 · Supplement to a New Drug Submission (SNDS)
- ITOVEBIJuly 16, 2026 · NOC 37929 · Supplement to a New Drug Submission (SNDS)
- COLUMVIJuly 10, 2026 · NOC 37867 · Supplement to a New Drug Submission (SNDS)
- RITUXAN SCMay 22, 2026 · NOC 37598 · Supplement to a New Drug Submission (SNDS)
- OCREVUSMay 15, 2026 · NOC 37548 · Supplement to a New Drug Submission (SNDS)
- PHESGOMay 13, 2026 · NOC 37528 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQ SCMay 11, 2026 · NOC 37515 · Supplement to a New Drug Submission (SNDS)
- ACTEMRAApril 22, 2026 · NOC 37372 · Supplement to a New Drug Submission (SNDS)
- EVRYSDIApril 22, 2026 · NOC 37383 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQ; TECENTRIQ SCApril 20, 2026 · NOC 37349 · Supplement to a New Drug Submission (SNDS)
- ROZLYTREKApril 20, 2026 · NOC 37367 · Supplement to a New Drug Submission (SNDS)
- LUNSUMIO SCApril 10, 2026 · NOC 37489 · New Drug Submission (NDS)
- POLIVYMarch 25, 2026 · NOC 37174 · Supplement to a New Drug Submission (SNDS)
- ENSPRYNGMarch 17, 2026 · NOC 37170 · Supplement to a New Drug Submission (SNDS)
- OCREVUSFebruary 17, 2026 · NOC 36924 · Supplement to a New Drug Submission (SNDS)
- CELLCEPT; CELLCEPT I.V.February 11, 2026 · NOC 36886 · Supplement to a New Drug Submission (SNDS)
- LUNSUMIOFebruary 6, 2026 · NOC 36883 · New Drug Submission (NDS)
- ROZLYTREKJanuary 22, 2026 · NOC 36773 · Supplement to a New Drug Submission (SNDS)
- GAZYVAJanuary 22, 2026 · NOC 36775 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQ; TECENTRIQ SCDecember 29, 2025 · NOC 36644 · Supplement to a New Drug Submission (SNDS)
- TNKASENovember 13, 2025 · NOC 36366 · Supplement to a New Drug Submission (SNDS)
- ITOVEBIOctober 1, 2025 · NOC 36088 · Supplement to a New Drug Submission (SNDS)
- COLUMVISeptember 16, 2025 · NOC 36011 · Supplement to a New Drug Submission (SNDS)
- COLUMVISeptember 15, 2025 · NOC 36009 · Supplement to a New Drug Submission (SNDS)
- COLUMVISeptember 10, 2025 · NOC 35983 · Supplement to a New Drug Submission (SNDS)
- KADCYLASeptember 5, 2025 · NOC 35959 · Supplement to a New Drug Submission (SNDS)
- EVRYSDIAugust 28, 2025 · NOC 35932 · Supplement to a New Drug Submission (SNDS)
- COLUMVIAugust 13, 2025 · NOC 35837 · Supplement to a New Drug Submission (SNDS)
- HEMLIBRAAugust 5, 2025 · NOC 35833 · Supplement to a New Drug Submission (SNDS)
- PHESGOAugust 1, 2025 · NOC 35790 · Supplement to a New Drug Submission (SNDS)
- VABYSMOJuly 25, 2025 · NOC 35769 · Supplement to a New Drug Submission (SNDS)
- PIASKYJune 4, 2025 · NOC 35476 · New Drug Submission (NDS)
- XOFLUZAMay 27, 2025 · NOC 35425 · Supplement to a New Drug Submission (SNDS)
- ACCUTANE ROCHEMay 16, 2025 · NOC 35362 · Supplement to a New Drug Submission (SNDS)
- HERCEPTIN; HERCEPTIN SCMay 2, 2025 · NOC 35308 · Supplement to a New Drug Submission (SNDS)
- ALECENSAROMarch 11, 2025 · NOC 34990 · Supplement to a New Drug Submission (SNDS)
- HEMLIBRAMarch 6, 2025 · NOC 34981 · Supplement to a New Drug Submission (SNDS)
- ITOVEBIFebruary 14, 2025 · NOC 34846 · New Drug Submission (NDS)
- KADCYLAJanuary 27, 2025 · NOC 34844 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQ; TECENTRIQ SCJanuary 9, 2025 · NOC 34663 · Supplement to a New Drug Submission (SNDS)
- VABYSMODecember 13, 2024 · NOC 34559 · Supplement to a New Drug Submission (SNDS)
- COLUMVIDecember 13, 2024 · NOC 34561 · Supplement to a New Drug Submission (SNDS)
- GAVRETONovember 15, 2024 · NOC 34378 · Supplement to a New Drug Submission (SNDS)
- EVRYSDIOctober 16, 2024 · NOC 34202 · Supplement to a New Drug Submission (SNDS)
- PERJETASeptember 18, 2024 · NOC 34032 · Supplement to a New Drug Submission (SNDS)
- VABYSMOJuly 24, 2024 · NOC 33699 · Supplement to a New Drug Submission (SNDS)
- POLIVYJuly 2, 2024 · NOC 33590 · Supplement to a New Drug Submission (SNDS)
- ALECENSAROJune 27, 2024 · NOC 33524 · Supplement to a New Drug Submission (SNDS)
- CATHFLOJune 11, 2024 · NOC 33444 · Supplement to a New Drug Submission (SNDS)
- GAZYVAJune 6, 2024 · NOC 33397 · Supplement to a New Drug Submission (SNDS)
- GAVRETOMay 30, 2024 · NOC 33342 · Supplement to a New Drug Submission (SNDS)
- GAVRETOMay 14, 2024 · NOC 33207 · Supplement to a New Drug Submission (SNDS)
- ALECENSAROMay 1, 2024 · NOC 33153 · Supplement to a New Drug Submission (SNDS)
- CELLCEPTApril 25, 2024 · NOC 33121 · Supplement to a New Drug Submission (SNDS)
- VABYSMOApril 15, 2024 · NOC 33062 · Supplement to a New Drug Submission (SNDS)
- ACTIVASE RT-PAMarch 22, 2024 · NOC 32933 · Supplement to a New Drug Submission (SNDS)
- PHESGOMarch 14, 2024 · NOC 32894 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQ; TECENTRIQ SCMarch 13, 2024 · NOC 32880 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQFebruary 19, 2024 · NOC 32731 · Supplement to a New Drug Submission (SNDS)
- RITUXAN SCFebruary 13, 2024 · NOC 32696 · Supplement to a New Drug Submission (SNDS)
- HERCEPTIN SCFebruary 13, 2024 · NOC 32697 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQDecember 15, 2023 · NOC 32361 · Supplement to a New Drug Submission (SNDS)
- ACTEMRA SCDecember 6, 2023 · NOC 32312 · Supplement to a New Drug Submission (SNDS)
- ESBRIETNovember 16, 2023 · NOC 32113 · Supplement to a New Drug Submission (SNDS)
- ROZLYTREKNovember 14, 2023 · NOC 32097 · Supplement to a New Drug Submission (SNDS)
- VABYSMOSeptember 13, 2023 · NOC 31616 · Supplement to a New Drug Submission (SNDS)
- OCREVUSAugust 21, 2023 · NOC 31462 · Supplement to a New Drug Submission (SNDS)
- AVASTINAugust 4, 2023 · NOC 31386 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQJune 26, 2023 · NOC 31063 · Supplement to a New Drug Submission (SNDS)
- RITUXANJune 2, 2023 · NOC 30919 · Supplement to a New Drug Submission (SNDS)
- RITUXAN SCJune 2, 2023 · NOC 30920 · Supplement to a New Drug Submission (SNDS)
- CATHFLOApril 18, 2023 · NOC 30542 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQApril 4, 2023 · NOC 30473 · Supplement to a New Drug Submission (SNDS)
- COTELLICMarch 28, 2023 · NOC 30411 · Supplement to a New Drug Submission (SNDS)
- XOFLUZAMarch 27, 2023 · NOC 30415 · Supplement to a New Drug Submission (SNDS)
- COLUMVIMarch 24, 2023 · NOC 30384 · New Drug Submission (NDS)
- TNKASEMarch 21, 2023 · NOC 30348 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQMarch 3, 2023 · NOC 30253 · Supplement to a New Drug Submission (SNDS)
- EVRYSDIMarch 1, 2023 · NOC 30252 · Supplement to a New Drug Submission (SNDS)
- XOFLUZAFebruary 27, 2023 · NOC 30219 · Supplement to a New Drug Submission (SNDS)
- NUTROPIN AQ NUSPINFebruary 14, 2023 · NOC 30124 · Supplement to a New Drug Submission (SNDS)
- GAZYVAFebruary 1, 2023 · NOC 30021 · Supplement to a New Drug Submission (SNDS)
- POLIVYJanuary 20, 2023 · NOC 29947 · Supplement to a New Drug Submission (SNDS)
- OCREVUSJanuary 9, 2023 · NOC 29863 · Supplement to a New Drug Submission (SNDS)
- HEMLIBRADecember 23, 2022 · NOC 29787 · Supplement to a New Drug Submission (SNDS)
- TECENTRIQDecember 21, 2022 · NOC 29758 · Supplement to a New Drug Submission (SNDS)
- EVRYSDIDecember 7, 2022 · NOC 29636 · Supplement to a New Drug Submission (SNDS)
- RITUXAN SCNovember 28, 2022 · NOC 29579 · Supplement to a New Drug Submission (SNDS)
- HERCEPTIN SCNovember 22, 2022 · NOC 29541 · Supplement to a New Drug Submission (SNDS)
- POLIVYNovember 14, 2022 · NOC 29456 · Supplement to a New Drug Submission (SNDS)
- KADCYLANovember 9, 2022 · NOC 29434 · Supplement to a New Drug Submission (SNDS)
- PULMOZYMENovember 4, 2022 · NOC 29400 · Supplement to a New Drug Submission (SNDS)
- PROLOPAOctober 31, 2022 · NOC 29351 · Supplement to a New Drug Submission (SNDS)
- ACTEMRA SCOctober 27, 2022 · NOC 29323 · Supplement to a New Drug Submission (SNDS)
- ACTEMRAOctober 13, 2022 · NOC 29188 · Supplement to a New Drug Submission (SNDS)
The latest 100 of 555.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- ALECENSARO (alectinib) and the Risk of Severe HypertriglyceridemiaApril 22, 2026 · Drugs · New safety information - Product safety - Adverse reaction
- ITOVEBI (inavolisib) and the Risk of Life-Threatening KetoacidosisOctober 9, 2025 · Drugs · New safety information - Labelling
- ESBRIET (pirfenidone) and the Risk of Drug-Induced Liver InjurySeptember 14, 2020 · Drugs · Product safety
- Hoffman-La Roche Herceptin Product Recall (2020-06-27)June 27, 2020 · Drugs - Biologic or vaccine · Product safety · Type I
- Important Safety Information on ACTEMRA® (tocilizumab) - Risk of HepatotoxicityMay 21, 2019 · Drugs - Biologic or vaccine
- TECENTRIQ® (atezolizumab) - Risk of Immune-Related MyositisMarch 13, 2019 · Biologic or vaccine · Product safety
- TECENTRIQ® (atezolizumab) - Risk of Immune-Related NephritisSeptember 18, 2018 · Biologic or vaccine · Product safety
- TECENTRIQ (atezolizumab) - Risk of MyocarditisFebruary 14, 2018 · Biologic or vaccine
- TARCEVA (erlotinib) - Use in Maintenance Treatment for PatientsJanuary 21, 2016 · Drugs · Product safety
- CellCept (mycophenolate mofetil) and MYFORTIC (mycophenolate sodium) - Serious Risk of Teratogenicity in Mycophenolate-Containing ProductsJanuary 18, 2016 · Drugs · Product safety
- ZELBORAF (vemurafenib) - Risk of Radiation Sensitization or Radiation Recall ReactionDecember 22, 2015 · Drugs · Product safety
- Skin-cancer drug Zelboraf (vemurafenib): new warning on the risk of pancreatitisFebruary 12, 2015 · Drugs · New safety information - Product safety
- ZELBORAF (vemurafenib) - Association with Liver Problems - For Health ProfessionalsApril 7, 2014 · Drugs · Product safety
- ZELBORAF (vemurafenib) - Association with Liver Problems - For the PublicApril 7, 2014 · Drugs · Product safety
- Kadcyla (trastuzumab emtansine) and Herceptin (trastuzumab) - Potential Risk for Medication Error Due to Name Confusion - For Health ProfessionalsOctober 9, 2013 · Biologic or vaccine · Product safety
- ZELBORAF (vemurafenib) - Risk of Progression of Certain Types of Cancer and Risk of Serious Rash - For the PublicAugust 20, 2013 · Drugs · Product safety
- ZELBORAF (vemurafenib) - Risk of Progression of Certain Types of Cancer and Risk of Serious Rash - For Health ProfessionalsAugust 20, 2013 · Drugs · Product safety
- RITUXAN (rituximab) - Hepatitis B Virus (HBV) Recurrence in Patients: Updates on Screening and Management - For Health ProfessionalsJuly 29, 2013 · Biologic or vaccine · Product safety
- RITUXAN (rituximab) - Hepatitis B Virus (HBV) Recurrence in Patients: Updates on Screening and Management - For the PublicJuly 29, 2013 · Biologic or vaccine · Product safety
- Cathflo (alteplase) - Particulate matter observed in some vials: additional instructions for use - Notice to HospitalsMay 10, 2013 · Biologic or vaccine · Contamination
- Avastin (bevacizumab) - Cases of Necrotizing Fasciitis Reported - For the PublicMay 2, 2013 · Biologic or vaccine · Product safety
- Avastin (bevacizumab) - Cases of Necrotizing Fasciitis Reported - For Health ProfessionalsMay 2, 2013 · Biologic or vaccine · Product safety
- RITUXAN (rituximab) - Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome - For the PublicFebruary 25, 2013 · Biologic or vaccine · New safety information
- RITUXAN (rituximab) - Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome - For Health ProfessionalsFebruary 25, 2013 · Biologic or vaccine · New safety information
- AVASTIN (bevacizumab) - Reports of Cases of Severe Eye Inflammation Leading to Blindness Following Use in the Eye - For Health ProfessionalsDecember 7, 2011 · Biologic or vaccine
- AVASTIN (bevacizumab) – Reports of Cases of Severe Eye Inflammation Leading to Blindness Following Use in the Eye – For the PublicDecember 7, 2011 · Biologic or vaccine
- Avastin (bevacizumab) - Health Canada has Suspended Approval for Use in Metastatic Breast Cancer - For Health ProfessionalsNovember 29, 2011 · Biologic or vaccine
- Avastin (bevacizumab) - Higher Incidence of New Cases of Ovarian Failure Observed in Premenopausal Women - For Health ProfessionalsNovember 14, 2011 · Biologic or vaccine
- AVASTIN (bevacizumab) – Higher Incidence of New Cases of Ovarian Failure Observed in Premenopausal Women – For the PublicNovember 14, 2011 · Biologic or vaccine
- RITUXAN (rituximab) - Fatal Infusion Related Reactions in Patients with Rheumatoid Arthritis - For Health ProfessionalsJune 7, 2011 · Biologic or vaccine
- RITUXAN (rituximab) – Fatal Infusion Related Reactions in Patients with Rheumatoid Arthritis – For the PublicJune 7, 2011 · Biologic or vaccine
- INVIRASE (saquinavir mesylate) - Need for electrocardiogram monitoring in patients - For Health ProfessionalsNovember 2, 2010 · Drugs
- INVIRASE (saquinavir mesylate) - Need for Electrocardiogram Monitoring in Patients - For the PublicNovember 2, 2010 · Drugs
- ACTEMRA (tocilizumab) - Risk of Fatal Anaphylaxis - For Health ProfessionalsSeptember 17, 2010 · Biologic or vaccine
- ACTEMRA (tocilizumab) - Risk of Fatal Anaphylaxis - For the PublicSeptember 17, 2010 · Biologic or vaccine
- AVASTIN (bevacizumab) - Association with Allergic Reactions - For Health ProfessionalsAugust 23, 2010 · Biologic or vaccine
- AVASTIN (bevacizumab) - Association with Allergic Reactions - For the PublicAugust 23, 2010 · Biologic or vaccine
- Invirase (saquinavir mesylate) - Association with Dose-Dependent Abnormal Electrical Activity or Conduction in the Heart (Prolongations of QT and PR Intervals) in Healthy Volunteers - For Health ProfessionalsApril 20, 2010 · Drugs
- Invirase (saquinavir mesylate) - Association with Dose-Dependent Abnormal Electrical Activity or Conduction in the Heart (Prolongations of QT and PR Intervals) in Healthy Volunteers - For the PublicApril 20, 2010 · Drugs
- Association of Rituxan (rituximab) with Progressive Multifocal Leukoencephalopathy (PML) - For Health ProfessionalsOctober 23, 2009 · Biologic or vaccine
- Archived - Association of Rituxan (rituximab) with Progressive Multifocal Leukoencephalopathy (PML) - For the PublicOctober 23, 2009 · Biologic or vaccine
- Archived – Important Tamiflu Information for Health ProfessionalsOctober 23, 2009 · Drugs · Labelling
- Association of CellCept (mycophenolate mofetil) with a potential risk of pure red cell aplasia (PRCA) - For Health ProfessionalsJune 4, 2009 · Drugs
- Archived - Association of CellCept (mycophenolate mofetil) with a potential risk of pure red cell aplasia (PRCA) - For the PublicJune 4, 2009 · Drugs
- Association of TARCEVA (erlotinib) with cases of gastrointestinal perforation, Stevens-Johnson syndrome, and corneal perforation - For Health ProfessionalsMay 11, 2009 · Drugs
- Archived - Association of TARCEVA (erlotinib) with cases of gastrointestinal perforation, Stevens-Johnson syndrome, and corneal perforation - For the PublicMay 11, 2009 · Drugs
- Association of Herceptin (trastuzumab) with Oligohydramnios - For Health ProfessionalsApril 24, 2009 · Drugs
- Archived – Association of HERCEPTIN® (trastuzumab) with Oligohydramnios – For the PublicApril 24, 2009 · Biologic or vaccine
- The use of Tarceva (erlotinib) in patients with moderate hepatic impairment and advanced solid tumours - For Health ProfessionalsDecember 17, 2008 · Drugs
- Archived - The use of Tarceva (erlotinib) in patients with moderate hepatic impairment and advanced solid tumours - For the PublicDecember 17, 2008 · Drugs
- Important Safety Information on RITUXAN (rituximab) - For Health ProfessionalsAugust 13, 2007 · Biologic or vaccine
- Archived - Association of AVASTIN (bevacizumab) with Tracheo-esophageal Fistula - For Health ProfessionalsJune 12, 2007 · Biologic or vaccine
- Archived - Association of AVASTIN® (bevacizumab) with Tracheo-esophageal Fistula - For the PublicJune 12, 2007 · Biologic or vaccine
- Archived – New information regarding TamifluNovember 29, 2006 · Drugs · Product safety
- Archived - AVASTIN® (bevacizumab) - Advisories, Warnings and Recalls for the PublicOctober 27, 2006 · Biologic or vaccine
- Archived - CellCept (mycophenolate mofetil) - Advisories, Warnings and Recalls for the PublicOctober 25, 2006 · Drugs
- Archived - Association of CellCept (mycophenolate mofetil) and sirolimus containing immunosuppressant regimen with higher rate of acute rejection in cardiac transplant patients switched from calcineurin inhibitorsOctober 25, 2006 · Drugs
- New Safety Information Regarding Fortovase and Invirase and Occurrence of Drug-Induced Hepatitis in Healthy Volunteers receiving Rifampin in combination with ritonavir boosted saquinavir.-Hoffmann-La Roche LimitedFebruary 18, 2005 · Drugs · New safety information
- Lariam (Mefloquine) – Updated Patient Information – Letter to Pharmacists – Hoffmann-La Roche LimitedJanuary 27, 2005 · Drugs · New safety information
- Lariam (Mefloquine) – Updated Patient Information – For Health ProfessionalsJanuary 27, 2005 · Drugs · New safety information
- Archived – Possible Association of RITUXAN (Rituximab) with Hepatitis B Reactivation – Hoffmann-La Roche LimitedJuly 30, 2004 · Biologic or vaccine · Product safety
- Archived – Possible Association Between RITUXAN® (Rituximab) and the Recurrence of Hepatitis B – Hoffmann-La Roche Limited – For the PublicJuly 30, 2004 · Biologic or vaccine · Product safety
- Archived - Important Drug Warning - RITUXAN - Hoffmann-La Roche Ltd.May 16, 2001 · Biologic or vaccine